Clinical Study
Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma
Table 1
Clinicopathologic characteristics of HCC patients.
| | Age (y) | | | Mean ± SD | | | Sex % | | | Male | 86.8 () | | Female | 13.2 () | | Tumor focality % | | | Solitary | 89.5 () | | Multiple | 10.5 () | | Tumor size (cm) | | | Mean ± SD | | | Histologic grade % | | | Well differentiated | 7.9 () | | Moderately differentiated | 71.1 () | | Poor differentiated | 21 () | | Nodal metastasis | | | Present | 15.8 () | | Absent | 84.2 () | | Vascular invasion | | | Present | 31.6 () | | Absent | 68.4 () | | Clinical T stage % | | | T1 | 21.1 () | | T2 | 21.1 () | | T3 | 39.5 () | | T4 | 18.3 () |
|
|
